Premium
Kelix Bio, an emerging markets-focused specialty generic biopharmaceutical company is looking to acquire five UAE-based pharma entities to further expand its product portfolio of affordable critical drugs, and scale growth. The deals would likely follow the enforcement of the Dubai-headquartered company’s acquisition by Abu Dhabi’s sovereign investor Mubadala Investment Company, announced ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
